Neratinib, an irreversible ErbB receptor tyrosine kinase inhibitor, shows efficacy in the treatment of HER2 amplified carcinosarcoma in vitro and in vivo

被引：1
|
作者：
Schwab, C. L. [1 ]
English, D. P. [1 ]
Black, J. D. [1 ]
Lopez, S. [2 ]
Bellone, S. [1 ]
Roque, D. M. [3 ]
Ratner, E. S. [1 ]
Silasi, D. A. [1 ]
Azodi, M. [1 ]
Rutherford, T. J. [1 ]
Schwartz, P. E. [1 ]
Santin, A. [1 ]
机构：
[1] Yale Univ, Sch Med, New Haven, CT USA
[2] Univ Campus Biomed Rome, Rome, Italy
[3] Univ Maryland, Sch Med, Baltimore, MD 21201 USA
来源：
GYNECOLOGIC ONCOLOGY | 2015年 / 137卷
关键词：
D O I：
10.1016/j.ygyno.2015.01.142
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
140
引用
收藏
页码：61 / 61
页数：1
相关论文
共 50 条
  • [21] ErbB2/HER2 receptor tyrosine kinase regulates human papillomavirus promoter activity
    Mikulicic, Snjezana
    Shamun, Merha
    Massenberg, Annika
    Franke, Anna-Lena
    Freitag, Kirsten
    Doering, Tatjana
    Strunk, Johannes
    Tenzer, Stefan
    Lang, Thorsten
    Florin, Luise
    FRONTIERS IN IMMUNOLOGY, 2024, 15
  • [22] Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2)-overexpressing breast cancer cells in vitro and in vivo
    Moulder, SL
    Yakes, FM
    Muthuswamy, SK
    Bianco, R
    Simpson, JF
    Arteaga, CL
    CANCER RESEARCH, 2001, 61 (24) : 8887 - 8895
  • [23] HER2-Mutated Breast Cancer Responds to Treatment With Single-Agent Neratinib, a Second-Generation HER2/EGFR Tyrosine Kinase Inhibitor
    Ben-Baruch, Noa Efrat
    Bose, Ron
    Kavuri, Shyam M.
    Ma, Cynthia X.
    Ellis, Matthew J.
    JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2015, 13 (09): : 1061 - 1064
  • [24] Biased activation of the receptor tyrosine kinase HER2
    Claudia Catapano
    Johanna V. Rahm
    Marjan Omer
    Laura Teodori
    Jørgen Kjems
    Marina S. Dietz
    Mike Heilemann
    Cellular and Molecular Life Sciences, 2023, 80
  • [25] Biased activation of the receptor tyrosine kinase HER2
    Catapano, Claudia
    Rahm, Johanna V.
    Omer, Marjan
    Teodori, Laura
    Kjems, Jorgen
    Dietz, Marina S.
    Heilemann, Mike
    CELLULAR AND MOLECULAR LIFE SCIENCES, 2023, 80 (06)
  • [26] Hyperactivation of mTORC1 drives acquired resistance to the pan HER tyrosine kinase inhibitor neratinib in HER2 mutant cancers
    Sudhan, Dhivya R.
    Hanker, Ariella B.
    Guerrero-Zotano, Angel
    Formisano, Luigi
    Guo, Yan
    Liu, Qi
    Avogadri-Connors, Francesca
    Cutler, Richard E.
    Lalani, Alshad S.
    Bryce, Richard
    Auerbach, Alan
    Arteaga, Carlos L.
    CANCER RESEARCH, 2018, 78 (13)
  • [27] Discovery of SPH5030, a Selective, Potent, and Irreversible Tyrosine Kinase Inhibitor for HER2-Amplified and HER2-Mutant Cancer Treatment
    Li, Di
    Tu, Yuanxiang
    Jin, Kaijun
    Duan, Lingjun
    Hong, Yuan
    Xu, Jia
    Chen, Na
    Zhang, Zhihui
    Zuo, Hongjian
    Gong, Wanchun
    Zhang, Jing
    Wang, Qian
    Qian, Hai
    Wang, Xuenan
    Ke, Ying
    Xia, Guangxin
    JOURNAL OF MEDICINAL CHEMISTRY, 2022, 65 (07) : 5334 - 5354
  • [28] Neratinib, an irreversible pan-ErbB receptor inhibitor, is highly effective against primary cervical cancer cell lines harboring HER2/neu gene mutations
    Lopez, S.
    Bellone, S.
    Black, J. D.
    Schwab, C. L.
    English, D. P.
    Terranova, C.
    Schwartz, P. E.
    Rutherford, T. J.
    Angioli, R.
    Santin, A.
    GYNECOLOGIC ONCOLOGY, 2015, 137 : 144 - 144
  • [29] Afatinib, an irreversible ErbB family inhibitor, demonstrates activity against HER2 mutated cervical cancer in vitro
    Lopez, Salvatore
    Cocco, Emiliano
    Stefania, Bellone
    Bortolomai, Ileana
    Bonazzoli, Elena
    Nicoletti, Roberta
    Schwab, Carlton
    English, Diana P.
    Terranova, Corrado
    Angioli, Roberto
    Santin, Alessandro D.
    CANCER RESEARCH, 2014, 74 (19)
  • [30] The Poly (ADP-ribose) polymerase inhibitor olaparib and pan-ErbB inhibitor neratinib are highly synergistic in HER2 overexpressing epithelial ovarian carcinoma in vitro and in vivo
    Han, Chanhee
    McNamara, Blair
    Bellone, Stefania
    Harold, Justin
    Manara, Paola
    Hartwich, Tobias Max Philipp
    Mutlu, Levent
    Yang-Hartwich, Yang
    Zipponi, Margherita
    Demirkiran, Cem
    Verzosa, Miguel Skyler
    Altwerger, Gary
    Ratner, Elena
    Huang, Gloria S.
    Clark, Mitchell
    Andikyan, Vaagn
    Azodi, Masoud
    Dottino, Peter R.
    Schwartz, Peter E.
    Santin, Alessandro D.
    GYNECOLOGIC ONCOLOGY, 2023, 170 : 172 - 178
12345